AEM vs DRD

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

DRD exhibits exceptional fundamental health, highlighted by a strong Piotroski F-Score of 8/9 and a pristine balance sheet with zero debt. While the stock trades at a premium to its Graham Number ($16.31), it remains significantly undervalued relative to its intrinsic value ($46.32) and analyst target price ($46.50). High profitability margins and an impressive ROE of 34.71% suggest a highly efficient operation. Despite a bearish technical trend and weak insider sentiment, the underlying financial strength and growth trajectory provide a compelling bullish case.